Mihaela Milicescu *, M. Bojincă *, A. Martin *, Şt. Milicescu **
* Mihaela Milicescu, M. Bojincă, A. Martin – Clinica de Medicină internă și Reumatologie, Spitalul “Dr. Ion Cantacuzino”, București
** Șt. Milicescu – Clinica de Protetică Dentară Fixă și Ocluzologie, U.M.F. “Carol Davila”, București
Abstract
The bisphosphonates are potent antiresorbtive drugs being indicated in glucocorticoid-induced osteoporosis. A 10 mg daily dose of sodium alendronate produces a significant increase in BMD after 1 year and 2 years of treatment, both in vertebral (L2-L4) and hip level in all three investigated areas in rheumatic diseases pacients receiving prednisone. The percentages obtained are greater after 2 years of treatment compared to those obtained by other authors [1], [2], [3], but the explanation could consist in the fact that the women in this study received suplimentary anabolic hormones (nandrolonum, 1 vial in 2 months). The reduction rate of vertebral fractures was of 66.6%, results in concordance with those presented in other studies. We noticed a significant reduction of non-axial fractures after 1 year and 2 years of treatment, even if 1 of 3 pacients experienced a fracture of this type at the initiation of the alendronate treatment. The bone resorbtion markers – hydroxiproline and calciuria – and bone forma tion ones – serum osteocalcin – significantly decrease, confirming the treatment eficacy.